Enovis Corporation (ENOV)
NYSE · Healthcare · Medical Devices
$18.69+5.18%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.1B
- Forward P/E
- 5.2
- 52-week range
- $17.30 – $34.28
- 52-week change
- −43.15%
- EPS (trailing)
- −$19.23
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $2.2B (+6.66%)
- Net income
- −$1.2B
- Operating margin
- −50.0%
- Diluted EPS
- −$20.75
- Free cash flow
- $19.9M
From the company’s annual report on SEC EDGAR.
About Enovis Corporation
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions.
Headquarters: Lewisville, United States · 7,802 employees · enovis.com